Home India Ministry of Health and Family Welfare Draft rules. These rules may be called the Drugs and Cosmeti...
Date: 2014-04-24 Category: Extra Ordinary State: Union Government Country: India

Draft rules. These rules may be called the Drugs and Cosmetics (Third Amendment) Rules, 2014.

Issued by Ministry of Health and Family Welfare · Department of Health and Family Welfare

Research with AI Agent Chat with Document Generate Summary Translate Helpful Share Add to Project Create Task

Executive Summary & Key Takeaways

Executive Summary: This notification publishes draft rules to further amend the Drugs and Cosmetics Rules, 1945, following consultations with the Drugs Technical Advisory Board. It addresses injury compensation, reporting of serious adverse events, and responsibilities of sponsors, investigators, and ethics committees in clinical trials. The draft rules will be considered after forty-five days from the date the Gazette of India is made available to the public. Key Points / Main Content: Clinical Trial Injury Compensation: * Free medical management must be provided for injuries occurring during clinical trials until it is established that the injury is unrelated to the trial or until recovery, whichever is earlier. * Compensation for non-permanent injuries should align with the nature of the injury, wage loss, and transportation costs. Responsibilities of Sponsors: * Sponsors must forward reports of serious adverse events, after due analysis, to the Licensing Authority, Ethics Committee Chairman, and Head of Institution within fourteen calendar days of occurrence. Responsibilities of Investigators: * Investigators failing to report serious adverse events within the specified period must provide a reason for the delay to the Licensing Authority. * The investigator must forward the report of the serious adverse event, after due analysis, to the Licensing Authority, Ethics Committee chairman, and the Head of the Institution within fourteen calendar days of the occurrence. Responsibilities of the Ethics Committee: * The Ethics Committee must forward its report on serious adverse events, including its opinion on financial compensation, to the Licensing Authority within thirty calendar days of the event. Serious Adverse Events: * The term "unexpected" is removed in relation to serious adverse events. * In case the Investigator fails to report any serious adverse event within the stipulated period, he shall have to furnish the reason for the delay to the satisfaction of the Licensing Authority along with the report of the serious adverse event. Schedule Y Amendments: * Clause iv of subparagraph 2 relating to Responsibilities of Sponsor, for clause iv, is substituted. Appendix V Amendments: * Clause a in serial number 1, in subserial number 1.1, in item number 9, is substituted. Appendix XII Amendments: * Serial number 1 is substituted. * Changes are made to serial numbers 2, 5, and 6 regarding injury compensation and reporting of adverse events, and failure to report. Reporting Timelines: * Specified timelines for reporting serious adverse events by investigators, sponsors, and ethics committees are outlined. Impact Analysis: Sponsors of Clinical Trials: * Impact: Increased responsibility for providing medical management and compensation for trial-related injuries and adhering to strict reporting timelines for serious adverse events. * Action Required: Update clinical trial protocols and procedures to comply with the new rules, including timelines for reporting and compensation. Investigators: * Impact: Greater accountability for timely reporting of serious adverse events and potential penalties for delays. * Action Required: Implement systems for tracking and reporting adverse events within the required timelines and be prepared to provide justifications for any delays. Ethics Committees: * Impact: Required to assess financial compensation for serious adverse events and adhere to stricter reporting timelines. * Action Required: Update review processes to include assessment of financial compensation and ensure timely reporting of serious adverse events to the Licensing Authority. Licensing Authority: * Impact: Oversight of serious adverse event reporting and implementation of the amended rules. * Action Required: Monitor compliance with the new reporting requirements, assess reasons for reporting delays, and ensure that appropriate actions are taken. Clinical Trial Subjects: * Impact: Enhanced protection through guaranteed medical management for trial-related injuries and potential for compensation. * Action Required: Be aware of their rights to medical management and compensation for injuries occurring during clinical trials.

Key Entities Referenced

Drugs and Cosmetics Rules, 1945: A set of rules in India related to the regulation of drugs and cosmetics, which is being amended by this notification. Drugs and Cosmetics Act, 1940: An act of the Indian Parliament to regulate the import, manufacture, distribution and sale of drugs and cosmetics. New Delhi: The location of the Ministry of Health and Family Welfare, where the notification was issued. Ministry of Health and Family Welfare: The ministry responsible for health policy in India, which issued the notification. Drugs Technical Advisory Board: A board that is consulted during the process of amending the Drugs and Cosmetics Rules. Gazette of India: The official government gazette where the notification and draft rules are published. Drugs and Cosmetics Third Amendment Rules, 2014: The title of the amendment rules being introduced in the notification. Licensing Authority: The authority responsible for issuing licenses related to clinical trials and drug regulations, as referenced in the amended rules.
Official Source Record View Original Source →
See Full Document Text
jftLVªh laö Mhö ,yö&33004@99 REGD. NO. D. L.-33004/99 vlk/kj.k EXTRAORDINARY Hkkx II—[k.M 3—mi&[k.M (i) PART II—Section 3—Sub-section (i) izkf/dkj ls izdkf'kr PUBLISHED BY AUTHORITY la- 222] ubZ fnYyh] c`gLifrokj] vizSy 24] 2014@oS'kk[k 4] 1936 No. 222] NEW DELHI, THURSDAY, APRIL 24, 2014/VAISAKHA 4, 1936 (cid:1)वा(cid:1)(cid:4)य और प(cid:10)रवार क(cid:12)याण म(cid:16)ं ालय ((cid:1)वा(cid:1)(cid:4)य और प(cid:10)रवार क(cid:12)याण (cid:19)वभाग) अ(cid:24)धसचू ना ubZ fnYyh] 24 vizSy] 2014 Lkk-dk-fu- 292 (v)-—ओष(cid:24)ध और साधन साम!ी #नयम, 1945 का और सशं ोधन करन े के ,लए #न.न,ल/खत ा2प #नयम, िजनको के567य सरकार, ओष(cid:24)ध और साधन अ(cid:24)ध#नयम, 1940 (1940 का 23) क; धारा 12 और धारा 33 <वारा द>त शि?तय@ का योग करत े हुए, ओष(cid:24)ध तकनीक; सलाहकार बोड E स े परामश E करन े के पF चात,् बनान े का (cid:1)ताव करती है, उन सभी Jयि?तय@ क; जानकार7 के ,लए का,शत Kकया जाता है, िजनके उसस े भा(cid:19)वत होन े क; सभं ावना है और यह सचू ना द7 जाती है Kक उ?त ा2प #नयम@ पर उस तार7ख स,े िजसको उस राजप(cid:16) क; #तया,ं िजसमL यह अ(cid:24)धसचू ना का,शत क; जाती है, जनता को उपलMध करा द7 जाती है, पतN ाल7स Oदन क; अव(cid:24)ध क; समािPत के पFच ात ् (cid:19)वचार Kकया जाएगा ; के567य सरकार <वारा उ?त ा2प #नयम@ के सबधं मL इस कार उपय?ुE त (cid:19)व#नOदESट अव(cid:24)ध के भीतर Kकसी Jयि?त स े ाPत आVेप@ और सझु ाव@ पर (cid:19)वचार Kकया जाएगा ; आVेप और सझु ाव, यOद कोई ह@, को स(cid:24)चव, (cid:1)वा(cid:1)(cid:4)य और प(cid:10)रवार क(cid:12)याण म(cid:16)ं ालय, भारत सरकार, #नमाEण भवन, नई Oद(cid:12)ल7-110011 को भेजा जा सकेगा । ा2प #नयम 1. इन #नयम@ का स\ं VPत नाम ओष(cid:24)ध और साधन साम!ी (ततृ ीय सशं ोधन) #नयम, 2014 है । 2. ओष(cid:24)ध और साधन साम!ी #नयम, 1945 (िजस े इसमL इसके पF चात ् उ?त #नयम कहा गया है),2 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(i)] (क) उ?त #नयम के #नयम 122घकख मL,-- (i) उप#नयम (1) के (cid:1)थान पर #न.न,ल/खत उप#नयम रखा जाएगा, अथाEत ् :- “(1) नदै ा#नक पर7Vण के दौरान Jयि?त को Kकसी V#त क; दशा मL उस े या उसको, िजतनी लबं ी अव(cid:24)ध के ,लए, जहा ं तक अपे\Vत हो, #नःश(cid:12)ु क (cid:24)चKक>सा का बधं Kकया जाएगा या ऐस े समय तक जब तक यह (cid:1)था(cid:19)पत हो जाता है Kक नदै ा#नक पर7Vण स े सबं (cid:24)ं धत V#त नह7 ं है, इसमL जो भी पवू >E तर हो ।” ; (ii) उपधारा (2) के पF चात ् #न.न,ल/खत उपधारा अतं ः(cid:1)था(cid:19)पत क; जाएगी, अथातE ् :- “2क. जहा ं कोई (cid:1)थायी V#त नह7 ं होन े क; दशा मL #तकर का प(cid:10)रमाण क; गणना V#त क; अ(cid:1)थायी कृ#त, मजदरू 7 और प(cid:10)रवहन क; V#त के अन2ु प होगी ।” ; (iii) उप#नयम (5) मL,-- (अ) खंड (ग) मL “आश#यत (cid:24)चKक>सा भाव दान करन े मL जांच उ>पाद क; (cid:19)वफलता” शMद@ के (cid:1)थान पर “मानक देखरेख क; दशा मL आश#यत (cid:24)चKक>सा भाव दान करन े मL जांच उ>पाद क; (cid:19)वफलता, नदै ा#नक पर7Vण नवाचार के अन2ु प रहत े हुए उपलMध नह7 ं कराई गई थी, के माhयम स े उपलMध होगा ।” रखा जाएगा । (आ) खंड (घ) मL “छj ओषध (Pला,सबो) #नयkं (cid:16)त पर7Vण मL छj उपयोग करना” शMद@ और कोठSक@ के (cid:1)थान पर “मानक देखरेख क; दशा मL, छj ओषध (Pला,सबो) #नयkं (cid:16)त पर7Vण मL छj उपयोग करना, नदै ा#नक पर7Vण नवाचार के अन2ु प रहत े हुए उपलMध नह7 ं कराई गई थी, के माhयम स े उपलMध होगा ।” (ख) अनसु चू ी म मL,- (क) ‘नदै ा#नक पर7Vण’ स े सबं (cid:24)ं धत परै ा 2 मL,-- (i) ायोजक के दा#य>व स े सबं (cid:24)ं धत उपपरै ा (2) मL, खंड (iv) के (cid:1)थान पर #न.न,ल/खत रखा जाएगा, अथाEत ् :- “(iv) गभं ीर #तकूल घटना क; कोई (cid:10)रपोटE अनpु Pत ा(cid:24)धकार7 को योजक <वारा स.यक् (cid:19)वF लषे ण के पF चात ् #नयम 21 के खंड 2 मL #नOदESट Kकए अनसु ार नी#त स,म#त के अhयV और स(cid:1)ं था के मखु , जहा ं पर7Vण सचं ा,लत Kकया जा रहा है, जहा ं गभं ीर #तकूल घटना घOटत हुई है, के 24 Oदन@ के भीतर भेजनी होगी ।” (ii) उप-परै ा (3) मL, अ5वेषक (को) के दा#य>व@ स े सबं (cid:24)ं धत, खंड (i) मL, “गभं ीर #तकूल घटना क; (cid:10)रपोटE” शMद@ के साथ शqु हो रहे भाग के ,लए और “गभं ीर #तकूल घटना के होन”े के शMद@ के साथ अ5त होन े वाल े भाग के (cid:1)थान पर #न.न,ल/खत रखा जाएगा, अथाEत “यOद अ5वेषण Kकसी गभं ीर #तकूल घटना क; #नयत अव(cid:24)ध के भीतर (cid:10)रपोटE करन े मL असफल रहता है, तो वह अनpु िPत ा(cid:24)धकार7 के समाधान होन े तक गभं ीर #तकूल घटना क; (cid:10)रपोटE के साथ देर7 का कारण देगा । अ5वेषक, #नयम क; धारा 21(ख) मL यथा#नOदESट अनpु िPत ा(cid:24)धकार7 को उ(cid:24)चत (cid:19)वFल षे ण के पF चात गभं ीर #तकूल घटना क; (cid:10)रपोटE अ!े(cid:19)षत करेगा, आचार स,म#त के अhयV¹Hkkx IIµ[k.M 3(i)º Hkkjr dk jkti=k % vlk/kj.k 3 और स(cid:1)ं था का मखु जहां पर यह पर7Vण सचं ा,लत Kकया गया था, गभं ीर #तकूल घटना होने के चौदह कैले5डर Oदवस@ के भीतर अ!े(cid:19)षत करेगी” (iii) उपपरै ा (5) मL, आचार स,म#त के दा#य>व@ स े सबं (cid:24)ं धत परै ा (iv) के (cid:1)थान पर #न.न,ल/खत परै ा रखा जाएगा, अथाEत-् “(iv) नदै ा#नक पर7Vण के अधीन JयिJतय@ के साथ होने वाल7 गभं ीर #तकूल घटना क; दशा मL, आचार स,म#त गभं ीर #तकूल घटना क; (cid:10)रपोटE, स.यक् (cid:19)वF लषे ण के पF चात ् (cid:19)व>तीय #तकर पर अपनी राय, यOद कोई हो, िजस े ायोजन या उसके #त#न(cid:24)ध <वारा सदं >त Kकए जान े है, िजसन े भी नदै ा#नक पर7Vण करने के ,लए #नयम क; धारा 21(ख) मL #नOदESट है, गभं ीर #तकूल घटना होन े के तीस कैलLडर Oदवस@ के भीतर गभं ीर #तकूल घटना के बारे मL अपनी (cid:10)रपोटE अ!े(cid:19)षत करेगा।” (iv) उप-परै ा 5(क) मL, गभं ीर #तकूल घटनाओ ं से सबं (cid:24)ं धत परै ा (2) मL, (i) शMद@ “और अ >या,शत” का लोप Kकया जाएगा। (ii) ‘और आदेश पा(cid:10)रत करL जैसा आवFयक समझ’े, शMद@ के पFच ात #न.न,ल/खत पनु ः(cid:1)था(cid:19)पत Kकया जाएगा, अथाEतः- “यOद अ5वेषक Kकसी गभं ीर #तकूल घटना को #नयत अव(cid:24)ध के भीतर (cid:10)रपोटE करन े मL असफल रहता है, तो वह गभं ीर #तकूल घटना क; (cid:10)रपोटE के साथ अनpु िPत ा(cid:24)धकार7 को उसके समाधान के ,लए देर7 का कारण देना होगा ।” (ख) प(cid:10)र,शSट V मL, sम सtं या मL, उप-sमांक 1.मL 1, मद स ं 9 .मL, खंड (क) के (cid:1)थान पर #न.न,ल/खत खंड रखा जाएगा, अथाEत-् “(क) नदै ा#नक पर7Vण के दौरान Jयि?त को Kकसी V#त क; दशा मL उस े या उसको, िजतनी लबं ी अव(cid:24)ध के ,लए, जहा ं तक अपे\Vत हो, नःश(cid:12)ु क (cid:24)चKक>सा का बधं Kकया जाएगा या ऐस े समय तक जब तक यह (cid:1)था(cid:19)पत हो जाता है Kक नदै ा#नक पर7Vण स े सबं (cid:24)ं धत V#त नह7 ं है, इसमL जो भी पवू >E तर हो ।” (ग) प(cid:10)र,शSट XII मL (i) s.स.ं (1) के (cid:1)थान पर, #न.न,ल/खत रखा जाएगा, अथाEत ् :- “(1) नदै ा#नक पर7Vण के दौरान Jयि?त को Kकसी V#त क; दशा मL उस े या उसको, िजतनी लबं ी अव(cid:24)ध के ,लए, जहा ं तक अपे\Vत हो, नःश(cid:12)ु क (cid:24)चKक>सा का बधं Kकया जाएगा या ऐस े समय तक जब तक यह (cid:1)था(cid:19)पत हो जाता है Kक नदै ा#नक पर7Vण स े सबं (cid:24)ं धत V#त नह7 ं है, इसमL जो भी पवू >E तर हो”; (ii) s.स.ं (2) मL, “Jयि?त के (cid:24)चKक>सा बधं न” शMद@ के पF चात ् ‘जहा ं कोई (cid:1)थायी V#त नह7 ं होने क; दशा मL #तकर का प(cid:10)रमाण क; गणना V#त क; अ(cid:1)थायी कृ#त, मजदरू 7 और प(cid:10)रवहन क; V#त के अन2ु प होगी” शMद रख े जाएंग;े (iii) s.स.ं (5) मL,- (क) खंड (घ) मL “आश#यत (cid:24)चKक>सा भाव दान करन े मL जांच उ>पाद क; (cid:19)वफलता” शMद@ के (cid:1)थान पर “मानक देखरेख क; दशा मL आश#यत (cid:24)चKक>सा भाव दान करन े मL जांच उ>पाद क; (cid:19)वफलता, नदै ा#नक पर7Vण नवाचार के अन2ु प रहत े हुए उपलMध नह7 ं कराई गई थी, के माhयम स े उपलMध होगा ।” शMद रख े जाएंग े ;4 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(i)] (ख) खंड (ड.) मL “छj ओषध (Pला,सबो) #नयkं (cid:16)त पर7Vण मL छj उपयोग करना” शMद@ और कोठSक@ के (cid:1)थान पर “मानक देखरेख क; दशा मL, छj ओषध (Pला,सबो) #नयkं (cid:16)त पर7Vण मL छj उपयोग करना, नदै ा#नक पर7Vण नवाचार के अन2ु प रहत े हुए उपलMध नह7ं कराई गई थी, के माhयम स े उपलMध होगा ; (iv) s.स.ं (6) मL,- (क) खंड (क) मL, (iii) शMद@ “और अ >या,शत” का लोप Kकया जाएगा। (iv) ‘और आदेश पा(cid:10)रत करL जसै ा आवFयक समझ’े, शMद@ के पF चात #न.न,ल/खत पनु ः(cid:1)था(cid:19)पत Kकया जाएगा, अथाEतः- “यOद अ5वेषक Kकसी गभं ीर #तकूल घटना को #नयत अव(cid:24)ध के भीतर (cid:10)रपोटE करन े मL असफल रहता है, तो वह गभं ीर #तकूल घटना क; (cid:10)रपोटE के साथ अनpु िPत ा(cid:24)धकार7 को उसके समाधान के ,लए देर7 का कारण देना होगा ।” (ख) खंड (ख) के, परै ा (i) मL (क) उपपरै ा (ख) मL (i) “(cid:10)रपोटE क; एक #त के साथ (cid:19)वशषे p समहू के अhयV” शMद@ का लोप Kकया जाएगा; (ii) “दस” शMद के (cid:1)थान पर “चौदह” शMद रख े जाएंग े । (ख) उपपरै ा (ग) मL, - (i) “(cid:10)रपोटE क; एक #त के साथ (cid:19)वशषे p समहू के अhयV” शMद@ का लोप Kकया जाएगा; (ii) “इक>तीस” शMद के (cid:1)थान पर “तीस” शMद रखा जाएगा । (ग) उप-परै ा (ग) के पF चात ् #न.न,ल/खत अतं ः(cid:1)था(cid:19)पत Kकया जाएगा, अथाEतः- “पर7Vणकता,E ायोजक अथवा उसके #त#न(cid:24)ध िजस Kकसी न े नदै ा#नक पर7Vण करन े के ,लए अनpु िPत ा(cid:24)धकार7 और आचार स,म#त तथा (cid:19)वशषे p समहू के अhयV स े अनमु #त ाPत क; थी, क; (cid:10)रपोटE अ!े(cid:19)षत करेगा” (घ) उपपरै ा (घ) मL, “आचार स,म#त स े (cid:10)रपोटE ाPत करन े के तीस Oदन@” शMद@ के (cid:1)थान पर “ #तकूल घटना क; ि(cid:1)थ#त के एक सौ पांच Oदन@” शMद रख े जाएंग े । (ड.) उपपरै ा (छ) मL, “गभं ीर #तकूल घटना क; (cid:10)रपोटE ाPत करन े के तीन मास” शMद@ के (cid:1)थान पर “ #तकूल घटना होन े के एक सौ पचास Oदन@” शMद@ स े #त(cid:1)था(cid:19)पत Kकया जाए। (ग) परै ा स.ं (ii) मL- (क) उप-परै ा (क) मL शMद “दस” के (cid:1)थान पर “चौदह” शMद रख े जाएंग;े (ख) उप-परै ा (ख) मL शMद “इ?क;स” के (cid:1)थान पर “तीस” शMद रख े जाएंग;े (ग) उप-परै ा (घ) मL, “गभं ीर #तकूल घटना क; (cid:10)रपोटE ाPत करन े के तीन माह” के (cid:1)थान पर “ #तकूल घटना होन े के एक सौ पचास Oदन@” शMद रख े जाएंग े । [फा.स.ं 18-2/2013- डीसी/डीएफ?यसू ी] अqण के.प| डा, सयं ?ु त स(cid:24)चव OटPपणीः मलू #नयम@ को भारत के राजप(cid:16) मL अ(cid:24)धसचू ना स.ं एफ.28-10/45-एच(1) तार7ख 21 Oदस.बर, 1945के <वारा का,शत Kकए गए और अ#ं तम सशं ोधन भारत के राजप(cid:16), असाधारण, भाग 2 खंड 3 मL स.ं सा.का.#न. 153 (अ) Oदनाँक 5 माच,E 2014 <वारा Kकया गया ।¹Hkkx IIµ[k.M 3(i)º Hkkjr dk jkti=k % vlk/kj.k 5 MINISTRY OF HEALTH AND FAMILY WELFARE (DEPARTMENT OF HEALTH AND FAMILY WELFARE) NOTIFICATION New Delhi, the 24th April, 2014 G.S.R. 292 (E).—The following draft rules further to amend the Drugs and Cosmetics Rules, 1945, which the Central Government proposes to make, in exercise of the powers conferred by section 12 and section 33 of the Drugs and Cosmetics Act, 1940 (23 of 1940), after consultation with the Drugs Technical Advisory Board, is hereby published for the information of all persons likely to be affected thereby, and the notice is hereby given that the said draft rules shall be taken into consideration on or after the expiry of a period of forty-five days from the date on which the copies of the Gazette of India containing these draft rules are made available to the public; The objections and suggestions which may be received from any person with respect to the said draft rules within the period specified above, will be considered by the Central Government; Objections and suggestions, if any, may be addressed to the Secretary, Ministry of Health and Family Welfare, Government of India, Nirman Bhawan, New Delhi- 110011. Draft rules 1. These rules may be called the Drugs and Cosmetics (Third Amendment) Rules, 2014. 2. In the Drugs and Cosmetics Rules, 1945, (hereinafter referred to as the said rules), (a) in rule 122-DAB of the said rules,- (i) for sub-rule (1), the following sub-rule shall be substituted, namely:— “(1) In the case of an injury occurring to the subject during the clinical trial, he or she shall be given free medical management as long as required or till such time it is established that the injury is not related to the clinical trial, whichever is earlier.”; (ii) after sub-rule (2), the following sub-rule shall be inserted, namely:- “(2A) In case there is no permanent injury, the quantum of compensation shall commensurate with the nature of the non-permanent injury, loss of wages and transportation.”; (iii) in sub-rule (5),- (A) in clause (c), after the words ‘therapeutic effect’, the words, “in case the standard care, though available, was not to be provided to the subject as per the clinical trial protocol.” shall be inserted; (B) in clause (d) after the words, ‘placebo controlled trial’, the words, “in case the standard care, though available, was not to be provided to the subject as per the clinical trial protocol.” shall be inserted; (b) in Schedule Y,- (a) in paragraph 2 relating to ‘Clinical Trial’,- (i) in sub-paragraph (2), relating to Responsibilities of Sponsor, for clause (iv), the following clause shall be substituted, namely:- “(iv) Any report of the serious adverse event, after due analysis shall be forwarded by the sponsor to the Licensing Authority as referred to in clause (b) of rule 21, Chairman of the Ethics Committee and the Head of the Institution where the trial has been conducted within fourteen calendar days of the occurrence of the serious adverse event.”; (ii) in sub-paragraph (3), relating to Responsibilities of the Investigator(s), in clause (i), for the portion beginning with the words “The report of the serious adverse event” and ending with the words “occurrence of the serious adverse event.” the following shall be substituted, namely:— “In case the Investigator fails to report any serious adverse event within the stipulated period, he shall have to furnish the reason for the delay to the satisfaction of the Licensing Authority along with the report of the serious adverse event. The report of the serious adverse event, after due analysis shall be forwarded by the investigator to the Licensing Authority as referred to in clause (b) of rule 21, chairman of the Ethics Committee and the Head of the Institution where the trial has been conducted within fourteen calendar days of the occurrence of the serious adverse event.”;6 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(i)] (iii) in sub-paragraph (5), relating to Responsibilities of the Ethics Committee, for clause (iv), the following clause shall be substituted, namely,- “(iv) In case of serious adverse event occurring to the clinical trial subjects, the Ethics Committee shall forward its report on the serious adverse event, after due analysis, along with its opinion on the financial compensation, if any, to be paid by the Sponsor or his representative, whosoever had obtained permission from the Licensing Authority as referred to in clause (b) of rule 21 for conducting the clinical trial, to the Licensing Authority within thirty calendar days of the occurrence of the serious adverse event.” (iv) in sub-paragraph 5(A), relating to Serious Adverse Events, in clause (2), (i) the words “and unexpected” shall be omitted. (ii) after the words ‘and pass orders as deemed necessary’, the following shall be inserted, namely:- “In case the Investigator fails to report any serious adverse event within the stipulated period, he shall have to furnish the reason for the delay to the satisfaction of the Licensing Authority along with the report of the serious adverse event.” (b) in APPENDIX V, in serial number 1, in sub-serial number 1.1, in item number 9, for clause (a), the following clause shall be substituted, namely:- “(a) In the case of an injury occurring to the subject during the clinical trial, he or she shall be given free medical management as long as required or till such time it is established that the injury is not related to the clinical trial, whichever is earlier.”. (c) in APPENDIX XII,- (i) for serial number (1), the following shall be substituted, namely:- “(1) In the case of an injury occurring to the subject during the clinical trial, he or she shall be given free medical management as long as required or till such time it is established that the injury is not related to the clinical trial, whichever is earlier.”; (ii) in serial number (2), after the words, “medical management of the subject.”, the words, “in case there is no permanent injury, the quantum of compensation shall commensurate with the nature of the non-permanent injury, loss of wages and transportation.” shall be inserted; (iii) in serial number (5),- (A) in clause (d), after the words, ‘therapeutic effect;’, the words, “in case the standard care, though available, was not to be provided to the subject as per the clinical trial protocol;” shall be inserted. (B) in clause (e), after the words ‘placebo-controlled trial’, the words, “in case the standard care, though available, was not to be provided to the subject as per the clinical trial protocol;” shall be inserted. (iv) in serial number (6),- (A) in clause (a), (i) the words, “and unexpected” shall be omitted; (ii) after the words ‘occurrence as per Appendix XI’, the following clause shall be inserted, namely:- “In case the Investigator fails to report any serious adverse event within the stipulated period, he shall have to furnish the reason for the delay to the satisfaction of the Licensing Authority along with the report of the serious adverse event.” (B) in clause (b), in para (i), (a) in sub-para (B),- (i) the words, “Chairman of the Expert Committee with a copy of the report to”, shall be omitted; (ii) for the word “ten”, the word “fourteen” shall be substituted; (b) in sub-para (C),- (i) the words “to the Chairman of the Expert Committee with a copy of the report”, shall be omitted;¹Hkkx IIµ[k.M 3(i)º Hkkjr dk jkti=k % vlk/kj.k 7 (ii) for the words “twenty one”, the word “thirty” shall be substituted; (c) after the sub-para (C), the following shall be inserted, namely,- “(CA) The Licensing Authority shall forward the reports of the investigator, sponsor or his representative whosoever had obtained permission from the Licensing Authority for conducting clinical trial and the Ethics Committee to the Chairman of the Expert Committee.”. (d) in sub-para (D), for the words “thirty days of receiving the reports from the Ethics Committee” the words, “one hundred and five days of the occurrence of the adverse event,” shall be substituted. (e) in sub-para (G), for the words “three months of receiving the report of the serious adverse event.”, the words, “one hundred fifty days of the occurrence of the adverse event.” shall be substituted. (C) in para number (ii),- (a) in sub-para (A) for the word “ten”, the word, “fourteen” shall be substituted; (b) in sub-para (B) for the words “twenty one”, the word, “thirty” shall be substituted; (c) in sub-para (D), for the words “three months of receiving the report of the serious adverse event.”, the words, “one hundred fifty days of the occurrence of the adverse event.”, shall be substituted. [F. No. 18-2/2013-DC/DFQC] ARUN K. PANDA, Joint Secy. Note.—The principal rules were published in the Gazette of India vide notification No. F.28-10/45-H (1) dated the 21st December, 1945 and was last amended by notification published in the Gazette of India, Extraordinary, Part II Section 3, Sub-section (i), vide number G.S.R. 153(E) dated the 5th March, 2014. Printed by the Manager, Government of India Press, Ring Road, Mayapuri, New Delhi-110064 and Published by the Controller of Publications, Delhi-110054

Continue your research